US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Agree

71.63

-0.2200-0.31%

Post-market: 71.630.00000.00%19:08 EDT

Volume:711.20K

Turnover:51.00M

Market Cap:7.87B

PE:40.50

High:72.56

Open:71.92

Low:71.51

Close:71.85

Loading ...

Overview Company News Filings

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

RTX, Nightwing Group Agree to Pay $8.4 Million to Settle Allegations Over Cybersecurity Requirements

MT Newswires Live

Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F

Analysts Offer Insights on Real Estate Companies: Alexandria Equities (ARE) and Agree Realty (ADC)

Vacasa Shareholders Agree to Accept Casago Buyout Offer During Special Meeting on Tuesday

MT Newswires Live

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

Should You Buy, Hold or Sell O Stock Amid Market Volatility?

ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Why Agree Realty, LCI Industries, And Allete Are Winners For Passive Income

Press Release: ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

BRIEF-Agree Realty Announces Exercise Of Underwriters' Option And Closing Of Forward Offering Of Common Stock

Agree Realty Announces Exercise of Underwriters' Option and Closing of Forward Offering of Common Stock

THOMSON REUTERS

Agree Realty Corp - Enters Forward Sale Agreement for 5,175,000 Shares With Bank of America, N.a.

THOMSON REUTERS

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Agree Realty Is Maintained at Outperform by Baird

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ADC/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"Agree","latestPrice":71.63,"timestamp":1752868800000,"preClose":71.85,"halted":0,"volume":711203,"hourTrading":{"tag":"盘后","latestPrice":71.63,"preClose":71.63,"latestTime":"19:08 EDT","volume":65592,"amount":4698362.16,"timestamp":1752880088835},"delay":0,"floatShares":107714195,"shares":109806548,"eps":1.768583,"marketStatus":"Not Yet Opened","change":-0.22,"latestTime":"07-18 16:00:00 EDT","open":71.92,"high":72.56,"low":71.51,"amount":50995886.5511,"amplitude":0.014614,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.768583,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":71.85,"dividendRate":0.042133,"preHourTrading":{"tag":"盘前","latestPrice":72.72,"preClose":71.85,"latestTime":"09:27 EDT","volume":181,"amount":13014.77242,"timestamp":1752845272641},"postHourTrading":{"tag":"盘后","latestPrice":71.63,"preClose":71.63,"latestTime":"19:08 EDT","volume":65592,"amount":4698362.16,"timestamp":1752880088835},"volumeRatio":0.5700052815856684,"impliedVol":0.0625,"impliedVolPercentile":0.02},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","floatShares":107714195,"roa":"2.30%","roe":"3.55%","lyrEps":1.793039,"volumeRatio":0.5700052815856684,"shares":109806548,"dividePrice":3.018,"high":72.56,"amplitude":0.014614,"preClose":71.85,"low":71.51,"week52Low":65.98,"pbRate":"1.44","psRate":"12.35","week52High":79.65,"institutionHeld":0.9993,"latestPrice":71.63,"eps":1.768583,"divideRate":0.042133,"volume":711203,"delay":0,"ttmEps":1.768583,"open":71.92,"prevYearClose":70.45,"prevWeekClose":71.62,"prevMonthClose":73.06,"prevQuarterClose":73.06,"fiveDayClose":71.62,"twentyDayClose":75.31,"sixtyDayClose":79.12,"earningDate":1753891200000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532882321","title":"Emmy-Winning Series Debuts Trailer for \"Shelter Me: The Cancer Pioneers\" Offering A Hopeful Look at Breakthrough Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2532882321","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532882321?lang=en_us&edition=fundamental","pubTime":"2025-05-02 21:32","pubTimestamp":1746192720,"startTime":"0","endTime":"0","summary":"LOS ANGELES, May 02, 2025----The official trailer for \"Shelter Me: The Cancer Pioneers\" has just dropped, giving audiences a moving first look at the groundbreaking new documentary that follows the emotional and inspiring journey of dogs helping to pioneer cancer treatments that are saving human lives. The movie will stream through the PBS app and on PBS.org starting on Thursday, May 15.\"This is one of the most powerful and consequential stories I’ve ever told,\" said Steven Latham, \"Shelter Me\" series Creator and Producer. \"Dogs are helping unlock the future of cancer treatment for people, and the results are incredibly promising.\". The official trailer captures the emotional stakes of the film: dogs that are beloved family members fighting cancer, dedicated and brave people, brilliant scientists and a future where hope comes on four legs. \"Shelter Me: The Cancer Pioneers\" is a powerful reminder of the unbreakable bond between humans and animals and how that relationship may hold the k","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/emmy-winning-series-debuts-trailer-133200780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","ADC","OS","BK4139","BK4231","DC","OSTX","BK4017","BK4097"],"gpt_icon":0},{"id":"2532221888","title":"RTX, Nightwing Group Agree to Pay $8.4 Million to Settle Allegations Over Cybersecurity Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2532221888","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532221888?lang=en_us&edition=fundamental","pubTime":"2025-05-02 00:19","pubTimestamp":1746116386,"startTime":"0","endTime":"0","summary":"RTX  and Nightwing Group agreed to pay $8.4 million to settle claims they failed to comply with certain cybersecurity requirements when working for the US Department of Defense, the Justice Department said Thursday.The Justice Department alleged RTX's former subsidiary Raytheon Cyber Solutions violated the False claims Act by failing to implement cybersecurity controls when performing unclassified work on certain Department of Defense contracts.The violations allegedly occurred between 2015 and 2021, prior to Nightwing's acquisition of RTX's cybersecurity, intelligence, and services business in 2024, the Justice Department said.The Justice Department added that its claims were allegations only and there had been no determination of liability.RTX did not immediately respond to a request for comment from MT Newswires.Price: 126.59, Change: +0.46, Percent Change: +0.36","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1585245621.USD","LU1430594728.SGD","BK4080","IE00B775SV38.USD","IE00B3S45H60.SGD","LU1280957306.USD","LU0787776722.HKD","BK4187","LU1929549753.HKD","LU0683600562.USD","BK4588","ADC","BK4550","LU0640476718.USD","BK4585","BK4566","RTX","BK4231","LU1162221912.USD","LU0320765646.SGD","LU1366192091.USD"],"gpt_icon":0},{"id":"2532050167","title":"Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F","url":"https://stock-news.laohu8.com/highlight/detail?id=2532050167","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532050167?lang=en_us&edition=fundamental","pubTime":"2025-04-30 23:30","pubTimestamp":1746027000,"startTime":"0","endTime":"0","summary":"Innate Pharma SA   today announced the filing of its 2024 Universal Registration Document  for the year ending December 31, 2024 with the French market authority \"Autorité des Marchés Financiers\"  on April 30, 2025. It can be downloaded  on the Company’s website and on the AMF’s website.The Company also announced today the filing of its annual report on Form 20-F for the year ending December 31, 2024 with the United States Securities and Exchange Commission . It can be also be accessed on the Company’s website and on the SEC’s website.Innate’s portfolio includes several ANKET drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/innate-pharma-files-2024-universal-153000086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPHYF","BK4075","BK4231","UVV","BK4139","BK4080","IPHA","ADC"],"gpt_icon":0},{"id":"2531942779","title":"Analysts Offer Insights on Real Estate Companies: Alexandria Equities (ARE) and Agree Realty (ADC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531942779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531942779?lang=en_us&edition=fundamental","pubTime":"2025-04-30 13:40","pubTimestamp":1745991611,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Real Estate sector with new ratings on Alexandria Equities (ARE – Research Report) and Agree Realty (AD...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-real-estate-companies-alexandria-equities-are-and-agree-realty-adc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-real-estate-companies-alexandria-equities-are-and-agree-realty-adc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADC","BK4225","BK4585","BK4588","BK4223","ARE","BK4231","BK4194","BK4080"],"gpt_icon":0},{"id":"2531791892","title":"Vacasa Shareholders Agree to Accept Casago Buyout Offer During Special Meeting on Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2531791892","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531791892?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:06","pubTimestamp":1745957162,"startTime":"0","endTime":"0","summary":"Vacasa  is expecting to close on its proposed merger with Casago at 11:59 pm on Wednesday, subject to completion or the wavier of any remaining conditions, after prospective deal was approved by 69% of its class A shares voted during a special shareholders meeting on Tuesday, the vacation rentals company said.Investors holding 96% of Vacasa's class B stock also agreed to accept Casago buyout offer that last month was increased to $5.30 per share from $5.02 per share under the original proposal disclosed by the companies on Dec. 30. As a group, 72% of all Vacasa shares sided with the deal, the company said.Price: 5.37, Change: -0.11, Percent Change: -1.92","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC","VCSA","BK4080","BK4539","BK4142","BK4231"],"gpt_icon":0},{"id":"2531125250","title":"Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531125250","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531125250?lang=en_us&edition=fundamental","pubTime":"2025-04-29 03:03","pubTimestamp":1745866980,"startTime":"0","endTime":"0","summary":"LOS ANGELES, April 28, 2025----Puma Biotechnology, Inc. , a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research  Annual Meeting 2025. The AACR Annual Meeting is currently taking place at the McCormick Place in Chicago, Illinois. The poster is entitled, \"CT071: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations .\" Andrew A. Davis, Assistant Professor at Washington University School of Medicine, presented the poster during Session PO.CT01.01 – First-in-Human Phase I Clinical Trials 1.Of 15 response-evaluable patients by RECIST v1.1, 4 patients had a partial response , including patients with gastro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/puma-biotechnology-presents-clinical-data-190300939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC","BK4213","PR","BK4080","BK4139","BK4231","PBYI"],"gpt_icon":0},{"id":"2531258730","title":"Should You Buy, Hold or Sell O Stock Amid Market Volatility?","url":"https://stock-news.laohu8.com/highlight/detail?id=2531258730","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531258730?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:24","pubTimestamp":1745853840,"startTime":"0","endTime":"0","summary":"Realty Income’s reputation as “The Monthly Dividend Company” is well-earned, backed by a solid history of dividend reliability and growth. The company has achieved 30 consecutive years of rising dividends and 110 straight quarterly increases, delivering a compound annual dividend growth rate of 4.3% since 1994. This strong track record showcases its resilience and makes Realty Income a compelling choice for income-focused investors seeking stable returns amid economic uncertainty. Check Realty Income’s dividend history here.Encouragingly, Realty Income’s dividend payouts are firmly supported by strong fundamentals. As of Dec. 31, 2024, the company owned 15,621 properties across all 50 U.S. states, the U.K. and six additional European markets. It boasts A3/A- credit ratings from Moody’s and S&P, respectively, alongside $3.7 billion in liquidity. With a manageable net debt to annualized pro-forma adjusted EBITDAre of 5.4X and a well-laddered debt maturity profile averaging 6.6 years, Rea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/buy-hold-sell-o-stock-152400171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4222","BK4231","BK4529","ADC","BK4080","BK4566","BK4585","DLR","BK4588","BK4084","O"],"gpt_icon":0},{"id":"2530236663","title":"ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2530236663","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530236663?lang=en_us&edition=fundamental","pubTime":"2025-04-28 22:00","pubTimestamp":1745848834,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA  is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower.While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.This company is expected to post quarterly loss of $0.38 per share in its upcoming report, which represents a year-over-year change of +32.1%.Revenues are expected to be $18.15 million, up 0.6% from the year-ago quarter.Please no","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adc-therapeutics-sa-adct-may-140034812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC","ADCT"],"gpt_icon":0},{"id":"2530815252","title":"Why  Agree Realty, LCI Industries, And Allete Are Winners For Passive Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2530815252","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530815252?lang=en_us&edition=fundamental","pubTime":"2025-04-28 21:39","pubTimestamp":1745847575,"startTime":"0","endTime":"0","summary":"Agree Realty  is a real estate investment trust that acquires and develops properties net leased to industry-leading, omnichannel retail tenants.Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!Agree Realty has increased its dividends consecutively for the last 12 years. In its most recent dividend announcement on April 10, it raised the monthly payout from $0.253 to $0.256 per share, equal to an annual figure of $3.072 per share. The dividend yield on the stock currently stands at 3.88%.Agree Realty’s annual revenue as of Dec. 31 stood at $617.10 million. According to its Q1 2025 earnings release on April 22, the company posted revenues of $169.16 million and AFFO of $1.06. Both figures came in above the consensus estimates.The company has raised its dividends every year for the last 14 years. As per its most recent dividend hike announcement on Jan. 30, its board increased th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-agree-realty-lci-industries-133935341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1868836914.USD","LU2023250843.SGD","LU2249611893.SGD","BK4581","IE00B19Z8X17.USD","LU0109391861.USD","ADC","BK4505","LU2065170008.USD","LU1934455194.USD","IE0004086264.USD","LU1429558221.USD","LU1244550494.USD","BK4081","BK4080","LU1037948897.HKD","LU0689472784.USD","LU2417539215.USD","BK4592","BK4573","IE00B19Z9505.USD","LU2290526834.HKD","ALE","LU1280957306.USD","IE0009G5SDU7.USD","SG9999014559.SGD","LU1935043536.SGD","LCII","BK4515","LU2420271590.USD","MACW.SI","LU2097344431.USD","TSYW.SI","LU1699723380.USD","LU2242650005.HKD","SG9999015945.SGD","IE00B3S45H60.SGD","LU0417517546.SGD","BK4585","LU1435385759.SGD","LU0820561818.USD","LU2381873111.SGD","LU2552382132.HKD","LU0082616367.USD","LU2471134796.USD","LU0308772762.SGD","LU0965509101.SGD","LU0823411888.USD"],"gpt_icon":1},{"id":"2530039724","title":"Press Release: ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2530039724","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530039724?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"NEWTOWN SQUARE, Pa., April 28, 2025  -- ArriVent BioPharma, Inc.  , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc.\"Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies across a broad array of therapeutic areas,\" said Bing Yao, Chairman and Chief Executive Officer of ArriVent. \"We are thrilled to have him join our Board of Directors at this important time and leverage his experience as firmonertinib progresses towards registration and we advance our antibody drug conjugate  pipeline.\". ArriVent is a clinical-stage biopha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4231","BK4080","ADC"],"gpt_icon":0},{"id":"2530472880","title":"ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530472880","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530472880?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:00","pubTimestamp":1745838000,"startTime":"0","endTime":"0","summary":"Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potentantitumor activity in ovarian and non-small lung cancer. Poster presentations highlightantitumor activity and safety of novel PSMA-targeted and ASCT2-targeted ADCs. ADCT-242 was tolerated in mice or cynomolgus monkeys at doses up to 150 mg/kg or 40 mg/kg, respectively, indicative of a good therapeutic index. Data from the preclinical investigation of ADCT-241, a novel PSMA-targeting ADC, were presented in a poster presentation titled, \"Preclinical Development of ADCT-241, a Novel Exatecan-based Antibody-Drug Conjugate Targeting PSMA for the Treatment of Prostate Cancer.\" The data demonstrated antitumor activity in both xenograft and patient-derived PSMA-expressing prostate cancer models as well as synergy with enzalutamide. ADCT-241 was well tolerated in both rats and cynomolgus monkeys.Data from the preclinical investigation of HuB14-VA-PL2202, a novel ASCT2-targetingADC, were presented in a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/adc-therapeutics-announces-preclinical-data-110000039.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adc-therapeutics-announces-preclinical-data-110000039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","LENZ","ADCT","BK4080","BK4139","BK4007","BK4117","BK4231","AFG","BK4505","ADC"],"gpt_icon":0},{"id":"2530414881","title":"Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530414881","media":"Business Wire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530414881?lang=en_us&edition=fundamental","pubTime":"2025-04-28 13:00","pubTimestamp":1745816400,"startTime":"0","endTime":"0","summary":"Pursuant to the article L. 233-8 II of the French \"Code de Commerce\" and the article 223-16 of the French stock-market authorities  General Regulation, Innate Pharma SA   releases its total number of shares outstanding as well as its voting rights as at April 25, 2025:.  The total number of theoretical voting rights  is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017. The total number of exercisable voting rights  is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is rel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/number-shares-voting-rights-innate-050000959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","ADC","BK4080","IPHYF","IPHA","BK4139"],"gpt_icon":0},{"id":"2530175929","title":"Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530175929","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530175929?lang=en_us&edition=fundamental","pubTime":"2025-04-27 01:30","pubTimestamp":1745688600,"startTime":"0","endTime":"0","summary":"Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care  Bacillus Calmette-Guérin  regimen compared to SOC alone. Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-nave, high-risk non-muscle invasive bladder cancer in more than 30 years. Results have been shared with global health authorities to support potential regulatory filings. \"New bladder cancer treatment options that help reduce rates of disease recurrence or progression are long overdue. Up to 50% of patients with high-risk non-muscle invasive bladder cancer may experience failure of BCG intravesical immunotherapy, yet it has been the standard of care after tumor resection for decades,\" said Neal Shore, M.D., FACS, Medical Director for START Carolina Research Center, and lead investigator ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-sasanlimab-combination-significantly-improves-173000786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4592","BK4550","LU1261432733.SGD","IE00BBT3K403.USD","SG9999001176.USD","SG9999003800.SGD","LU1023059063.AUD","LU0289739699.SGD","BK4203","LU0170899867.USD","IE0002270589.USD","LU0122379950.USD","BCG","IE000M9KFDE8.USD","CI","BK4097","BK4231","LU0234572021.USD","LU1894683348.USD","BK4585","IE00BSNM7G36.USD","HR","LU1057294990.SGD","BK4007","LU0985481810.HKD","BK4533","LU1066053197.SGD","BK4135","IE00BLSP4239.USD","SOC","LU0225771236.USD","BK4581","SG9999002224.SGD","BK4588","LU1059921491.USD","ADC","LU0456855351.SGD","SGXZ57979304.SGD","CR","LU0321505439.SGD","PFE","SG9999013999.USD","SG9999002232.USD","LU1883839398.USD","LU0306806265.USD","BK4213","SG9999011175.SGD","BK4534","OS"],"gpt_icon":1},{"id":"2530198149","title":"BRIEF-Agree Realty Announces Exercise Of Underwriters' Option And Closing Of Forward Offering Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2530198149","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530198149?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:53","pubTimestamp":1745614404,"startTime":"0","endTime":"0","summary":"BRIEF-Agree Realty Announces Exercise Of Underwriters' Option And Closing Of Forward Offering Of Common StockApril 25 (Reuters) - Agree Realty Corp ADC.N:AGREE REALTY ANNOUNCES EXERCISE OF UNDERWRITER","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA2RKMJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4231","BK4080"],"gpt_icon":0},{"id":"2530679731","title":"Agree Realty Announces Exercise of Underwriters' Option and Closing of Forward Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2530679731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530679731?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:05","pubTimestamp":1745611503,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA2RKMJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADC","BK4080","BK4231"],"gpt_icon":0},{"id":"2530160326","title":"Agree Realty Corp - Enters Forward Sale Agreement for 5,175,000 Shares With Bank of America, N.a.","url":"https://stock-news.laohu8.com/highlight/detail?id=2530160326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530160326?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:05","pubTimestamp":1745611503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA2RKMJP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADC","BK4231","BK4080"],"gpt_icon":0},{"id":"2530168669","title":"Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2530168669","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530168669?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:17","pubTimestamp":1745601420,"startTime":"0","endTime":"0","summary":"Gene signatures associated with increased efficacy of micvotabart pelidotin  due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders. Mouse analog of MICVO in a syngeneic model indicated strong activity of the cytotoxic Auristatin0101 payload and potential for MICVO monotherapy to drive immunogenic cell death, a key hypothesis for MICVO’s mechanism. Combination of a mouse analog of MICVO and anti-PD-1 therapy in a syngeneic model resulted in enhanced tumor clearance and longer immunological memory compared to either treatment alone. Totality of pre-clinical data presented at AACR 2025 strongly support MICVO’s unique, three-pronged mechanism of action of driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death, further reinforcing the potential patient benefit for MICVO as a monotherapy and in combination with an anti-PD-1 therapy. Key findings from preclinical studies of MICV","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pyxis-oncology-presents-promising-preclinical-171700556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4559","SG9999001176.USD","LU0106261372.USD","LU2089984988.USD","PYXS","LU1069347547.HKD","SG9999014542.SGD","LU0266013472.USD","LU1941712264.USD","LU2023250843.SGD","LU0861579265.USD","BK4550","LU0203345920.USD","LU0320765646.SGD","LU1585245621.USD","LU2361044865.SGD","LU0965509010.AUD","PACI.U","IE000M9KFDE8.USD","LU0211331839.USD","IE00BLSP4239.USD","IE00BJT1NW94.SGD","LU1941712348.USD","IE00B1BXHZ80.USD","MRK","ADC","LU0965509101.SGD","BK4007","LU0985320562.USD","BK4533","LU0006306889.USD","LU2112291526.USD","IE00B2B36J28.USD","LU1430594728.SGD","LU2324357040.USD","LU0070302665.USD","LU0058720904.USD","LU1291159041.SGD","LU0965509283.SGD","LU1066051225.USD","L","SG9999014575.USD","LU2361045086.USD","IE00B4R5TH58.HKD","IE00BBT3K403.USD","LU0238689110.USD","SG9999002224.SGD","IE0009355771.USD","LU1116320901.HKD","LU2361044949.HKD"],"gpt_icon":0},{"id":"2530601168","title":"Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530601168","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530601168?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:12","pubTimestamp":1745601120,"startTime":"0","endTime":"0","summary":"- Findings support advancement of ZL-6201 into Investigational New Drug -enabling studies in 2025 as a potential first-in-class and best-in-class antibody-drug conjugate  treatment for patients with leucine-rich repeat-containing protein 15 -positive solid tumors. - Data from preclinical studies suggest ZL-1222, a novel anti-PD-1/interleukin-12  immunocytokine, induces potent anti-tumor activity through cis-activation of T cells in the tumor microenvironment and efficiently blocks PD-1/PD-L1 signaling pathway with improved systemic safety. Findings to be presented at AACR 2025 on Tuesday, April 29, demonstrate that ZL-6201 efficiently internalizes within and kills tumor cells, while also exhibiting a strong bystander killing effect in the tumor microenvironment where the target is often expressed. In multiple in vitro and in vivo pre-clinical studies, treatment with ZL-6201 effectively suppressed the growth of established tumors. Based on these findings, Zai Lab plans to initiate Inves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zai-lab-presents-data-highlighting-171200295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC","BK4231","BK4080","BK4139","BK4526","BK4531","BK4548","ZLAB","LU2488822045.USD","BK4585","BK4588"],"gpt_icon":0},{"id":"2530716857","title":"Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530716857","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530716857?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:00","pubTimestamp":1745600400,"startTime":"0","endTime":"0","summary":"-- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors --. \"We designed EO-1022 with several notable features, including glycan site-specific conjugation and MMAE payloads, in order to address the significant need for a novel HER3 ADC that can potentially deliver improved efficacy and safety to patients with a range of solid tumors,\" saidJoseph Ferra, President and Chief Executive Officer of Elevation Oncology. \"Today, we are excited to share preclinical proof-of-concept data for EO-1022, which indicate enhanced stability and anti-tumor activity than benchmark HER3 ADCs in the models tested in vitro and in vivo. We believe these findings support the potential of EO-1022 in treating multiple HER3-expressing cancers and look forward to progressing this program toward the clinic.\". EO-1022 elicits anti-tumor activity in in vivo models of low, medium and high HER3 expression levels, including in a patient derived xenogra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/elevation-oncology-presents-preclinical-proof-170000523.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elevation-oncology-presents-preclinical-proof-170000523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1721429741.USD","LU1721429402.USD","LU0256331488.USD","DAR","AFG","BK4117","BK4539","LU2211817866.USD","PACI.U","BK4080","BK4107","LU2308191902.HKD","BK4139","ELEV","BK4231","ADC","BK4189","PDX","LU2380233275.USD"],"gpt_icon":0},{"id":"2530156180","title":"Agree Realty Is Maintained at Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2530156180","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530156180?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:31","pubTimestamp":1745595060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 25, 2025 11:31 ET (15:31 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC\",params:#limit:5,,,undefined,":[{"date":"2025-07-31","symbol":"ADC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":1.03,"defaultRemindTime":1753992000000,"name":null,"time":"Post Market","dateTimestamp":1753934400000,"actualEps":null},{"date":"2025-07-31","symbol":"ADC","amount":0.256,"announcedDate":"2025-07-10","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-31","defaultRemindTime":1753968600000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-14","payableDate":"2025-07-31","currency":"USD","dateTimestamp":1753934400000,"payDate":"2025-08-14"},{"date":"2025-06-30","symbol":"ADC","amount":0.256,"announcedDate":"2025-06-10","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-30","defaultRemindTime":1751290200000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-15","payableDate":"2025-06-30","currency":"USD","dateTimestamp":1751256000000,"payDate":"2025-07-15"},{"date":"2025-05-30","symbol":"ADC","amount":0.256,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-30","defaultRemindTime":1748611800000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-13","payableDate":"2025-05-30","currency":"USD","dateTimestamp":1748577600000,"payDate":"2025-06-13"},{"date":"2025-04-30","symbol":"ADC","amount":0.256,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-30","defaultRemindTime":1746019800000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-14","payableDate":"2025-04-30","currency":"USD","dateTimestamp":1745985600000,"payDate":"2025-05-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC\",market:\"US\",,,undefined,":[{"executeDate":"2015-09-28","recordDate":"2015-09-30","paymentDate":"2015-10-13","value":0.465,"currency":"USD"},{"executeDate":"2015-12-18","recordDate":"2015-12-22","paymentDate":"2016-01-05","value":0.465,"currency":"USD"},{"executeDate":"2016-03-29","recordDate":"2016-03-31","paymentDate":"2016-04-15","value":0.465,"currency":"USD"},{"executeDate":"2016-06-28","recordDate":"2016-06-30","paymentDate":"2016-07-15","value":0.48,"currency":"USD"},{"executeDate":"2016-09-28","recordDate":"2016-09-30","paymentDate":"2016-10-14","value":0.48,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.381,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.381,"analysts":21,"updateTime":1752206400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ADC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ADC","date":"2025-07-18","current":41.234702,"percent":0.550489,"low":31.539495,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"high":53.261716,"avg":41.095165,"sd":4.464973,"marketCap":7889600473},"quantilePoints":[{"date":"2020-07-24","current":37.537078,"twenty":30.71291,"median":36.149452,"eighty":43.037844,"marketCap":3365424257},{"date":"2020-07-31","current":40.350852,"twenty":30.745133,"median":36.199495,"eighty":43.037844,"marketCap":3617696027},{"date":"2020-08-07","current":41.351038,"twenty":30.776927,"median":36.250246,"eighty":43.037844,"marketCap":3707368648},{"date":"2020-08-14","current":40.224323,"twenty":30.922362,"median":36.348523,"eighty":43.037844,"marketCap":3606351900},{"date":"2020-08-21","current":40.308676,"twenty":31.08368,"median":36.544296,"eighty":43.037844,"marketCap":3613914651},{"date":"2020-08-28","current":40.628012,"twenty":31.203975,"median":36.640352,"eighty":43.037844,"marketCap":3642545066},{"date":"2020-09-04","current":40.013441,"twenty":31.296906,"median":36.781594,"eighty":43.037844,"marketCap":3587445022},{"date":"2020-09-11","current":40.079718,"twenty":31.383772,"median":36.974643,"eighty":43.037844,"marketCap":3593387184},{"date":"2020-09-18","current":38.59149,"twenty":31.509762,"median":37.052903,"eighty":43.037844,"marketCap":3459958646},{"date":"2020-09-25","current":37.645532,"twenty":31.534039,"median":37.273263,"eighty":43.037844,"marketCap":3375147794},{"date":"2020-10-02","current":39.29644,"twenty":31.704694,"median":37.362034,"eighty":43.037844,"marketCap":3523161638},{"date":"2020-10-09","current":40.368928,"twenty":31.803276,"median":37.497873,"eighty":43.037844,"marketCap":3619316617},{"date":"2020-10-16","current":39.386818,"twenty":31.867808,"median":37.57347,"eighty":43.037844,"marketCap":3531264585},{"date":"2020-10-23","current":40.224079,"twenty":31.975443,"median":37.612137,"eighty":43.037844,"marketCap":3633239960},{"date":"2020-10-30","current":38.164301,"twenty":31.975443,"median":37.733323,"eighty":43.037844,"marketCap":3447190528},{"date":"2020-11-06","current":38.797606,"twenty":31.975443,"median":37.935059,"eighty":43.037844,"marketCap":3504393786},{"date":"2020-11-13","current":41.26934,"twenty":31.975443,"median":38.046028,"eighty":43.037844,"marketCap":3727653105},{"date":"2020-11-20","current":40.039622,"twenty":31.975443,"median":38.167733,"eighty":43.037844,"marketCap":3616578817},{"date":"2020-11-27","current":40.506914,"twenty":31.975443,"median":38.310136,"eighty":43.037844,"marketCap":3658787046},{"date":"2020-12-04","current":40.580698,"twenty":31.975443,"median":38.471704,"eighty":43.037844,"marketCap":3665451504},{"date":"2020-12-11","current":40.230228,"twenty":31.975443,"median":38.545534,"eighty":43.037844,"marketCap":3633795331},{"date":"2020-12-18","current":39.344831,"twenty":31.975443,"median":38.676992,"eighty":43.037844,"marketCap":3553821844},{"date":"2020-12-24","current":39.762935,"twenty":31.975443,"median":38.782235,"eighty":43.037844,"marketCap":3591587102},{"date":"2020-12-31","current":40.937316,"twenty":31.975443,"median":38.892751,"eighty":43.037844,"marketCap":3697663047},{"date":"2021-01-08","current":45.450661,"twenty":31.975443,"median":39.008592,"eighty":43.047885,"marketCap":4105330986},{"date":"2021-01-15","current":44.653159,"twenty":31.975443,"median":39.245492,"eighty":43.22631,"marketCap":4033296550},{"date":"2021-01-22","current":45.359718,"twenty":31.975443,"median":39.341757,"eighty":43.313411,"marketCap":4097116533},{"date":"2021-01-29","current":44.212433,"twenty":31.975443,"median":39.41667,"eighty":43.4163,"marketCap":3993488046},{"date":"2021-02-05","current":46.262155,"twenty":31.975443,"median":39.41667,"eighty":43.554978,"marketCap":4178629185},{"date":"2021-02-12","current":45.520618,"twenty":31.975443,"median":39.41667,"eighty":43.618647,"marketCap":4111649797},{"date":"2021-02-19","current":43.859591,"twenty":31.975443,"median":39.41667,"eighty":43.642628,"marketCap":4007933303},{"date":"2021-02-26","current":44.718497,"twenty":31.977009,"median":39.430911,"eighty":43.756513,"marketCap":4086420942},{"date":"2021-03-05","current":44.656157,"twenty":31.975443,"median":39.41667,"eighty":43.796506,"marketCap":4080724259},{"date":"2021-03-12","current":46.594043,"twenty":31.975443,"median":39.41667,"eighty":43.856021,"marketCap":4257810284},{"date":"2021-03-19","current":46.240217,"twenty":31.975443,"median":39.41667,"eighty":43.889974,"marketCap":4225477299},{"date":"2021-03-26","current":46.69811,"twenty":31.977009,"median":39.430911,"eighty":43.995818,"marketCap":4267319985},{"date":"2021-04-01","current":47.239256,"twenty":31.977009,"median":39.430911,"eighty":44.083322,"marketCap":4316770432},{"date":"2021-04-09","current":47.1005,"twenty":31.975443,"median":39.41667,"eighty":44.146464,"marketCap":4304090831},{"date":"2021-04-16","current":47.627771,"twenty":31.975443,"median":39.41667,"eighty":44.201737,"marketCap":4352273317},{"date":"2021-04-23","current":49.334461,"twenty":31.975443,"median":39.41667,"eighty":44.216631,"marketCap":4508232419},{"date":"2021-04-30","current":48.814129,"twenty":31.975443,"median":39.41667,"eighty":44.274005,"marketCap":4460683913},{"date":"2021-05-07","current":44.881383,"twenty":31.975443,"median":39.41667,"eighty":44.314742,"marketCap":4499986938},{"date":"2021-05-14","current":44.377456,"twenty":31.975443,"median":39.41667,"eighty":44.249425,"marketCap":4449461218},{"date":"2021-05-21","current":44.026621,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4414285084},{"date":"2021-05-28","current":44.830352,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4494870410},{"date":"2021-06-04","current":45.665977,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4578653566},{"date":"2021-06-11","current":45.646841,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4576734868},{"date":"2021-06-18","current":47.246871,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4737160278},{"date":"2021-06-25","current":48.748389,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4887708512},{"date":"2021-07-02","current":48.211648,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4833892628},{"date":"2021-07-09","current":49.210395,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4934031046},{"date":"2021-07-16","current":49.93058,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5006239701},{"date":"2021-07-23","current":50.956505,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5109102975},{"date":"2021-07-30","current":53.056971,"twenty":31.977009,"median":39.430911,"eighty":44.230599,"marketCap":5165308396},{"date":"2021-08-06","current":52.598062,"twenty":31.977009,"median":39.430911,"eighty":44.296692,"marketCap":5120631744},{"date":"2021-08-13","current":52.520401,"twenty":31.977009,"median":39.430911,"eighty":44.412506,"marketCap":5113071079},{"date":"2021-08-20","current":52.718085,"twenty":31.977009,"median":39.430911,"eighty":44.625208,"marketCap":5132316407},{"date":"2021-08-27","current":52.209754,"twenty":31.977009,"median":39.430911,"eighty":44.658936,"marketCap":5082828422},{"date":"2021-09-03","current":52.675724,"twenty":31.977009,"median":39.430911,"eighty":44.712504,"marketCap":5128192408},{"date":"2021-09-10","current":49.555141,"twenty":31.977009,"median":39.430911,"eighty":44.74795,"marketCap":4824391169},{"date":"2021-09-17","current":50.119952,"twenty":31.977009,"median":39.430911,"eighty":44.835833,"marketCap":4879377818},{"date":"2021-09-24","current":47.775985,"twenty":31.977009,"median":39.430911,"eighty":44.888065,"marketCap":4651183223},{"date":"2021-10-01","current":47.352376,"twenty":31.977009,"median":39.430911,"eighty":44.941549,"marketCap":4609943235},{"date":"2021-10-08","current":47.670083,"twenty":31.977009,"median":39.430911,"eighty":44.9864,"marketCap":4640873226},{"date":"2021-10-15","current":49.02563,"twenty":31.977009,"median":39.430911,"eighty":45.094688,"marketCap":4772841185},{"date":"2021-10-22","current":49.5269,"twenty":31.977009,"median":39.430911,"eighty":45.190701,"marketCap":4821641836},{"date":"2021-10-29","current":50.169373,"twenty":32.013133,"median":39.571166,"eighty":45.28245,"marketCap":4884189150},{"date":"2021-11-05","current":43.773853,"twenty":32.013133,"median":39.651928,"eighty":45.28245,"marketCap":4934976633},{"date":"2021-11-12","current":43.137928,"twenty":32.029424,"median":39.72736,"eighty":45.28245,"marketCap":4863283742},{"date":"2021-11-19","current":43.008274,"twenty":32.198132,"median":39.802558,"eighty":45.28245,"marketCap":4848666745},{"date":"2021-11-26","current":42.662528,"twenty":32.27459,"median":39.842867,"eighty":45.28245,"marketCap":4809688086},{"date":"2021-12-03","current":42.508177,"twenty":32.348817,"median":39.911012,"eighty":45.28245,"marketCap":4792286899},{"date":"2021-12-10","current":42.891493,"twenty":32.447032,"median":39.953188,"eighty":45.28245,"marketCap":4835501148},{"date":"2021-12-17","current":45.380751,"twenty":32.521786,"median":39.996581,"eighty":45.380751,"marketCap":5116135105},{"date":"2021-12-23","current":46.352906,"twenty":32.588031,"median":40.079057,"eighty":45.406143,"marketCap":5225733953},{"date":"2021-12-31","current":48.175698,"twenty":32.64443,"median":40.10618,"eighty":45.47788,"marketCap":5431231792},{"date":"2022-01-07","current":46.703962,"twenty":32.651599,"median":40.164071,"eighty":45.565296,"marketCap":5265311314},{"date":"2022-01-14","current":46.015352,"twenty":32.70478,"median":40.208708,"eighty":45.667046,"marketCap":5187678797},{"date":"2022-01-21","current":43.267663,"twenty":32.731462,"median":40.224323,"eighty":45.667046,"marketCap":4877909831},{"date":"2022-01-28","current":43.821252,"twenty":32.743358,"median":40.249944,"eighty":45.667046,"marketCap":4940320287},{"date":"2022-02-04","current":42.666817,"twenty":32.769192,"median":40.314701,"eighty":45.667046,"marketCap":4810171655},{"date":"2022-02-11","current":42.565551,"twenty":32.769192,"median":40.347561,"eighty":45.667046,"marketCap":4798755108},{"date":"2022-02-18","current":42.943612,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4841376882},{"date":"2022-02-25","current":37.784604,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4620036905},{"date":"2022-03-04","current":38.267307,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4679058463},{"date":"2022-03-11","current":37.29027,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4559593141},{"date":"2022-03-18","current":37.24956,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4554615419},{"date":"2022-03-25","current":38.110019,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4659826391},{"date":"2022-04-01","current":39.298046,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4805089927},{"date":"2022-04-08","current":39.763938,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4862056020},{"date":"2022-04-14","current":40.742313,"twenty":32.769192,"median":40.404479,"eighty":45.667046,"marketCap":4981684815},{"date":"2022-04-22","current":42.01187,"twenty":32.769192,"median":40.455317,"eighty":45.667046,"marketCap":5136917418},{"date":"2022-04-29","current":39.554287,"twenty":32.79826,"median":40.479695,"eighty":45.667046,"marketCap":4836421278},{"date":"2022-05-06","current":39.499614,"twenty":32.904642,"median":40.479695,"eighty":45.667046,"marketCap":5066773466},{"date":"2022-05-13","current":39.967203,"twenty":32.996397,"median":40.479695,"eighty":45.667046,"marketCap":5126753027},{"date":"2022-05-20","current":39.90291,"twenty":33.05702,"median":40.479695,"eighty":45.667046,"marketCap":5118505838},{"date":"2022-05-27","current":40.353768,"twenty":33.088236,"median":40.495181,"eighty":45.667046,"marketCap":5176339242},{"date":"2022-06-03","current":40.599257,"twenty":33.156377,"median":40.53176,"eighty":45.667046,"marketCap":5207829139},{"date":"2022-06-10","current":41.119461,"twenty":33.227354,"median":40.613635,"eighty":45.667046,"marketCap":5274557730},{"date":"2022-06-17","current":40.213488,"twenty":33.270165,"median":40.613635,"eighty":45.667046,"marketCap":5158345016},{"date":"2022-06-24","current":43.32302,"twenty":33.260026,"median":40.659236,"eighty":45.668114,"marketCap":5557217043},{"date":"2022-07-01","current":42.978166,"twenty":33.330747,"median":40.684242,"eighty":45.668114,"marketCap":5512981235},{"date":"2022-07-08","current":42.872956,"twenty":33.466784,"median":40.715658,"eighty":45.668114,"marketCap":5499485565},{"date":"2022-07-15","current":43.708789,"twenty":33.59929,"median":40.742313,"eighty":45.668114,"marketCap":5606701167},{"date":"2022-07-22","current":44.556311,"twenty":33.59929,"median":40.778643,"eighty":45.668114,"marketCap":5715416287},{"date":"2022-07-29","current":46.520226,"twenty":33.675236,"median":40.820493,"eighty":45.678143,"marketCap":5967335462},{"date":"2022-08-05","current":43.100932,"twenty":33.675236,"median":40.862996,"eighty":45.68777,"marketCap":6116022220},{"date":"2022-08-12","current":44.318758,"twenty":33.675236,"median":40.912721,"eighty":45.68777,"marketCap":6288831702},{"date":"2022-08-19","current":44.509569,"twenty":33.675236,"median":40.969109,"eighty":45.68777,"marketCap":6315907842},{"date":"2022-08-26","current":43.241234,"twenty":33.675236,"median":41.010201,"eighty":45.68777,"marketCap":6135931147},{"date":"2022-09-02","current":41.585665,"twenty":33.675236,"median":41.060268,"eighty":45.68777,"marketCap":5901005814},{"date":"2022-09-09","current":41.956063,"twenty":33.675236,"median":41.092655,"eighty":45.68777,"marketCap":5953565380},{"date":"2022-09-16","current":40.805583,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5790312183},{"date":"2022-09-23","current":39.935707,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5666876838},{"date":"2022-09-30","current":37.927001,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5381841428},{"date":"2022-10-07","current":36.428553,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5169211706},{"date":"2022-10-14","current":35.631626,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5056127734},{"date":"2022-10-21","current":36.636203,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5198677248},{"date":"2022-10-28","current":38.359137,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5443161610},{"date":"2022-11-04","current":41.724424,"twenty":33.675236,"median":41.119461,"eighty":45.68777,"marketCap":6035896875},{"date":"2022-11-11","current":42.347632,"twenty":33.675236,"median":41.160749,"eighty":45.68777,"marketCap":6126050848},{"date":"2022-11-18","current":42.756995,"twenty":33.675236,"median":41.197005,"eighty":45.68777,"marketCap":6185269635},{"date":"2022-11-25","current":43.056379,"twenty":33.675236,"median":41.218321,"eighty":45.68777,"marketCap":6228578896},{"date":"2022-12-02","current":43.196907,"twenty":33.675236,"median":41.257018,"eighty":45.68777,"marketCap":6248907733},{"date":"2022-12-09","current":43.795676,"twenty":33.675236,"median":41.35326,"eighty":45.68777,"marketCap":6335526256},{"date":"2022-12-16","current":43.172467,"twenty":33.675236,"median":41.423201,"eighty":45.68777,"marketCap":6245372283},{"date":"2022-12-23","current":43.685698,"twenty":33.675236,"median":41.463369,"eighty":45.68777,"marketCap":6319616732},{"date":"2022-12-30","current":43.337434,"twenty":33.675236,"median":41.483593,"eighty":45.68777,"marketCap":6269236570},{"date":"2023-01-06","current":43.245786,"twenty":34.167053,"median":41.539601,"eighty":45.68777,"marketCap":6255978633},{"date":"2023-01-13","current":45.714181,"twenty":34.992765,"median":41.587683,"eighty":45.704396,"marketCap":6613059075},{"date":"2023-01-20","current":45.402576,"twenty":35.880519,"median":41.605991,"eighty":45.714503,"marketCap":6567982088},{"date":"2023-01-27","current":45.378137,"twenty":36.169649,"median":41.646285,"eighty":45.714503,"marketCap":6564446638},{"date":"2023-02-03","current":45.255939,"twenty":36.592515,"median":41.674422,"eighty":45.714503,"marketCap":6546769389},{"date":"2023-02-10","current":44.406665,"twenty":36.713651,"median":41.711398,"eighty":45.714503,"marketCap":6423912504},{"date":"2023-02-17","current":44.157808,"twenty":36.89773,"median":41.739833,"eighty":45.714503,"marketCap":6731283715},{"date":"2023-02-24","current":42.410386,"twenty":36.963658,"median":41.754028,"eighty":45.714503,"marketCap":6464912060},{"date":"2023-03-03","current":41.690165,"twenty":37.214665,"median":41.783816,"eighty":45.714503,"marketCap":6355123742},{"date":"2023-03-10","current":39.423241,"twenty":37.286636,"median":41.783816,"eighty":45.714503,"marketCap":6009560514},{"date":"2023-03-17","current":40.355986,"twenty":37.342014,"median":41.783816,"eighty":45.714503,"marketCap":6151745384},{"date":"2023-03-24","current":39.606247,"twenty":37.466803,"median":41.783816,"eighty":45.714503,"marketCap":6037457546},{"date":"2023-03-31","current":40.621801,"twenty":37.536428,"median":41.78137,"eighty":45.714342,"marketCap":6192265465},{"date":"2023-04-06","current":39.692254,"twenty":37.577737,"median":41.783816,"eighty":45.714503,"marketCap":6050568092},{"date":"2023-04-14","current":39.289647,"twenty":37.687654,"median":41.784219,"eighty":45.714663,"marketCap":5989195981},{"date":"2023-04-21","current":39.792905,"twenty":37.872566,"median":41.784621,"eighty":45.714824,"marketCap":6065911119},{"date":"2023-04-28","current":40.118543,"twenty":37.943837,"median":41.797292,"eighty":45.714985,"marketCap":6115550327},{"date":"2023-05-05","current":39.964605,"twenty":38.110019,"median":41.797292,"eighty":45.714985,"marketCap":6092084520},{"date":"2023-05-12","current":39.104119,"twenty":38.249787,"median":41.797292,"eighty":45.714985,"marketCap":6176026400},{"date":"2023-05-19","current":38.898029,"twenty":38.342909,"median":41.797292,"eighty":45.714985,"marketCap":6143476946},{"date":"2023-05-26","current":37.796919,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5969569863},{"date":"2023-06-02","current":37.832249,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5975149770},{"date":"2023-06-09","current":38.668386,"twenty":38.476762,"median":41.797292,"eighty":45.714985,"marketCap":6107207554},{"date":"2023-06-16","current":38.786152,"twenty":38.533217,"median":41.797292,"eighty":45.714985,"marketCap":6125807242},{"date":"2023-06-23","current":38.509402,"twenty":38.553397,"median":41.809962,"eighty":45.718688,"marketCap":6082097976},{"date":"2023-06-30","current":38.55062,"twenty":38.5799,"median":41.81327,"eighty":45.72239,"marketCap":6088607866},{"date":"2023-07-07","current":38.662498,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6106277570},{"date":"2023-07-14","current":38.603615,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6096977726},{"date":"2023-07-21","current":39.357316,"twenty":38.659115,"median":41.81327,"eighty":45.72239,"marketCap":6216015729},{"date":"2023-07-28","current":39.404422,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6223455604},{"date":"2023-08-04","current":38.053978,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6196443469},{"date":"2023-08-11","current":37.511193,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6108060089},{"date":"2023-08-18","current":36.166029,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5889023018},{"date":"2023-08-25","current":36.531819,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5948585730},{"date":"2023-09-01","current":36.472821,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5938978841},{"date":"2023-09-08","current":35.75304,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5821774794},{"date":"2023-09-15","current":35.446248,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5771818971},{"date":"2023-09-22","current":33.711695,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5489376431},{"date":"2023-09-29","current":32.567126,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5303002783},{"date":"2023-10-06","current":32.649724,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5316452427},{"date":"2023-10-13","current":31.806046,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5179073913},{"date":"2023-10-20","current":32.41963,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5278985560},{"date":"2023-10-27","current":33.181375,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5472604212},{"date":"2023-11-03","current":35.377246,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5834769220},{"date":"2023-11-10","current":34.598655,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5706356142},{"date":"2023-11-17","current":35.425908,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5842795038},{"date":"2023-11-24","current":35.170433,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5800659496},{"date":"2023-12-01","current":36.015934,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5940108073},{"date":"2023-12-08","current":36.873602,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6081563104},{"date":"2023-12-15","current":37.7556,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6227031044},{"date":"2023-12-22","current":37.968496,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6262143995},{"date":"2023-12-29","current":38.607184,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":6367482847},{"date":"2024-01-05","current":38.296964,"twenty":38.756995,"median":41.871582,"eighty":45.73451,"marketCap":6316318262},{"date":"2024-01-12","current":38.090151,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":6282208538},{"date":"2024-01-19","current":36.989174,"twenty":38.764196,"median":41.872103,"eighty":45.735522,"marketCap":6100624420},{"date":"2024-01-26","current":36.295741,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":5986256523},{"date":"2024-02-02","current":37.232484,"twenty":38.697827,"median":41.871582,"eighty":45.73451,"marketCap":6140753507},{"date":"2024-02-09","current":35.261674,"twenty":38.661168,"median":41.871582,"eighty":45.73451,"marketCap":5815707904},{"date":"2024-02-16","current":33.847315,"twenty":38.629468,"median":41.871582,"eighty":45.73451,"marketCap":5752655855},{"date":"2024-02-23","current":33.670228,"twenty":38.597685,"median":41.871582,"eighty":45.73451,"marketCap":5722558249},{"date":"2024-03-01","current":32.436519,"twenty":38.556509,"median":41.871061,"eighty":45.733498,"marketCap":5512878257},{"date":"2024-03-08","current":33.758772,"twenty":38.535146,"median":41.871061,"eighty":45.733498,"marketCap":5737607052},{"date":"2024-03-15","current":32.6018,"twenty":38.489062,"median":41.871061,"eighty":45.733498,"marketCap":5540969356},{"date":"2024-03-22","current":33.262927,"twenty":38.456408,"median":41.871061,"eighty":45.733498,"marketCap":5653333754},{"date":"2024-03-28","current":33.457723,"twenty":38.385748,"median":41.784621,"eighty":45.733498,"marketCap":5686441121},{"date":"2024-04-05","current":33.192092,"twenty":38.338315,"median":41.766476,"eighty":45.73451,"marketCap":5641294711},{"date":"2024-04-12","current":33.499043,"twenty":38.271415,"median":41.746116,"eighty":45.73451,"marketCap":5693463896},{"date":"2024-04-19","current":32.99201,"twenty":38.226469,"median":41.73308,"eighty":45.73451,"marketCap":5607289064},{"date":"2024-04-26","current":33.647761,"twenty":38.150217,"median":41.720309,"eighty":45.733498,"marketCap":5827926731},{"date":"2024-05-03","current":33.618779,"twenty":38.090151,"median":41.711398,"eighty":45.733498,"marketCap":5822906984},{"date":"2024-05-10","current":34.482434,"twenty":38.029323,"median":41.69585,"eighty":45.733498,"marketCap":5972495456},{"date":"2024-05-17","current":34.986715,"twenty":37.950247,"median":41.66791,"eighty":45.733498,"marketCap":6059839061},{"date":"2024-05-24","current":34.198413,"twenty":37.871294,"median":41.619337,"eighty":45.733498,"marketCap":5923301932},{"date":"2024-05-31","current":34.928752,"twenty":37.820473,"median":41.602226,"eighty":45.733498,"marketCap":6049799566},{"date":"2024-06-07","current":35.908334,"twenty":37.7418,"median":41.585665,"eighty":45.733498,"marketCap":6219467028},{"date":"2024-06-14","current":35.311311,"twenty":37.642264,"median":41.478607,"eighty":45.73451,"marketCap":6116060232},{"date":"2024-06-21","current":35.485201,"twenty":37.563829,"median":41.447441,"eighty":45.735522,"marketCap":6146178716},{"date":"2024-06-28","current":35.734443,"twenty":37.537078,"median":41.447441,"eighty":45.738558,"marketCap":6189348544},{"date":"2024-07-05","current":35.879352,"twenty":37.482188,"median":41.447441,"eighty":45.738558,"marketCap":6214447281},{"date":"2024-07-12","current":36.957471,"twenty":37.418215,"median":41.439295,"eighty":45.738558,"marketCap":6401181884},{"date":"2024-07-15","current":37.189325,"twenty":37.412399,"median":41.439295,"eighty":45.738558,"marketCap":6441339863},{"date":"2024-08-02","current":37.993919,"twenty":37.339153,"median":41.40142,"eighty":45.707657,"marketCap":7107142493},{"date":"2024-08-09","current":38.417922,"twenty":37.339153,"median":41.351038,"eighty":45.669183,"marketCap":7186456557},{"date":"2024-08-16","current":38.455492,"twenty":37.339153,"median":41.248609,"eighty":45.587895,"marketCap":7193484385},{"date":"2024-08-23","current":38.879496,"twenty":37.339153,"median":41.197005,"eighty":45.51208,"marketCap":7272798449},{"date":"2024-08-30","current":39.104915,"twenty":37.339153,"median":41.152223,"eighty":45.432939,"marketCap":7314965420},{"date":"2024-09-06","current":40.19981,"twenty":37.339153,"median":41.109476,"eighty":45.406991,"marketCap":7519776420},{"date":"2024-09-13","current":40.725789,"twenty":37.339153,"median":41.060268,"eighty":45.379705,"marketCap":7618166018},{"date":"2024-09-20","current":39.786541,"twenty":37.339153,"median":41.020981,"eighty":45.296882,"marketCap":7442470307},{"date":"2024-09-27","current":39.931453,"twenty":37.339153,"median":40.992653,"eighty":45.271719,"marketCap":7469577645},{"date":"2024-10-04","current":40.355457,"twenty":37.339153,"median":40.937316,"eighty":45.211095,"marketCap":7548891709},{"date":"2024-10-11","current":39.3196,"twenty":37.339153,"median":40.894276,"eighty":45.159517,"marketCap":7355124439},{"date":"2024-10-18","current":40.731156,"twenty":37.339153,"median":40.838938,"eighty":45.089028,"marketCap":7619169993},{"date":"2024-10-25","current":42.532506,"twenty":37.339153,"median":40.820493,"eighty":45.046981,"marketCap":8077475775},{"date":"2024-10-31","current":40.816625,"twenty":37.339153,"median":40.816625,"eighty":44.988744,"marketCap":7751607762},{"date":"2024-11-08","current":40.076878,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7611120201},{"date":"2024-11-15","current":41.115788,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7808422584},{"date":"2024-11-22","current":41.948003,"twenty":37.338438,"median":40.773001,"eighty":44.914929,"marketCap":7966471090},{"date":"2024-11-29","current":41.773945,"twenty":37.338438,"median":40.773001,"eighty":44.914324,"marketCap":7933415193},{"date":"2024-12-06","current":40.849261,"twenty":37.338438,"median":40.770318,"eighty":44.892115,"marketCap":7757805742},{"date":"2024-12-13","current":40.055121,"twenty":37.338438,"median":40.736734,"eighty":44.892115,"marketCap":7606988214},{"date":"2024-12-20","current":37.770608,"twenty":37.338438,"median":40.680888,"eighty":44.892115,"marketCap":7173129570},{"date":"2024-12-27","current":38.515795,"twenty":37.338438,"median":40.640959,"eighty":44.892115,"marketCap":7314650128},{"date":"2025-01-03","current":37.933788,"twenty":37.338438,"median":40.614232,"eighty":44.892115,"marketCap":7204119473},{"date":"2025-01-10","current":37.906591,"twenty":37.337724,"median":40.580698,"eighty":44.89414,"marketCap":7198954490},{"date":"2025-01-17","current":39.244663,"twenty":37.333873,"median":40.538993,"eighty":44.89414,"marketCap":7453071695},{"date":"2025-01-24","current":38.87479,"twenty":37.333873,"median":40.501145,"eighty":44.89414,"marketCap":7382827915},{"date":"2025-01-31","current":39.761398,"twenty":37.333873,"median":40.465332,"eighty":44.84311,"marketCap":7551206388},{"date":"2025-02-07","current":39.74508,"twenty":37.333873,"median":40.424995,"eighty":44.718497,"marketCap":7548107398},{"date":"2025-02-14","current":40.634976,"twenty":37.333873,"median":40.403761,"eighty":44.67404,"marketCap":7688015540},{"date":"2025-02-21","current":40.363435,"twenty":37.333873,"median":40.374953,"eighty":44.653159,"marketCap":7636640801},{"date":"2025-02-28","current":41.687197,"twenty":37.333873,"median":40.374953,"eighty":44.559412,"marketCap":7887092651},{"date":"2025-03-07","current":42.394335,"twenty":37.33306,"median":40.37194,"eighty":44.562299,"marketCap":8020881032},{"date":"2025-03-14","current":42.767704,"twenty":37.33306,"median":40.383179,"eighty":44.562299,"marketCap":8091521298},{"date":"2025-03-21","current":43.141073,"twenty":37.417052,"median":40.40791,"eighty":44.562299,"marketCap":8162161563},{"date":"2025-03-28","current":42.993988,"twenty":37.479862,"median":40.452151,"eighty":44.562299,"marketCap":8134333580},{"date":"2025-04-04","current":43.440899,"twenty":37.536428,"median":40.487288,"eighty":44.562299,"marketCap":8218887836},{"date":"2025-04-11","current":41.268572,"twenty":37.537078,"median":40.501145,"eighty":44.559412,"marketCap":7807889929},{"date":"2025-04-17","current":44.145605,"twenty":37.540692,"median":40.519212,"eighty":44.559412,"marketCap":8352216066},{"date":"2025-04-25","current":43.782817,"twenty":37.571542,"median":40.572736,"eighty":44.653759,"marketCap":8377141546},{"date":"2025-05-02","current":45.953462,"twenty":37.571542,"median":40.583839,"eighty":44.677947,"marketCap":8792459672},{"date":"2025-05-09","current":43.031008,"twenty":37.571542,"median":40.598117,"eighty":44.677947,"marketCap":8233294969},{"date":"2025-05-16","current":42.422675,"twenty":37.571542,"median":40.624906,"eighty":44.677947,"marketCap":8116900028},{"date":"2025-05-23","current":42.755537,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8180587826},{"date":"2025-05-30","current":42.698147,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8169607171},{"date":"2025-06-06","current":42.411197,"twenty":37.571542,"median":40.666871,"eighty":44.666838,"marketCap":8114703897},{"date":"2025-06-13","current":42.927706,"twenty":37.571542,"median":40.666871,"eighty":44.666838,"marketCap":8213529790},{"date":"2025-06-20","current":43.220395,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":8269531129},{"date":"2025-06-27","current":41.894687,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":8015878004},{"date":"2025-07-03","current":41.30357,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7902777259},{"date":"2025-07-11","current":40.735409,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7794068777},{"date":"2025-07-18","current":41.234702,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7889600473}],"updateTime":1753047489187}}}